Baiyang Pharmaceutical released its 2026 semi-annual report on the evening of August 28. In the first half of the year, it achieved operating revenue of 3.56 billion yuan, or 4.068 billion yuan after restating for the two-invoice system. Net profit attributable to shareholders of the listed company was 225 million yuan, up 37.72% year on year, while non-GAAP net profit attributable to the parent company was 221 million yuan, up 24.58%. The company continued to focus on its own-brand operations, with brand operation revenue of 2.722 billion yuan, a gross margin of 48.59%, and gross profit accounting for 93.27% of the total. Diqiao brand revenue reached 1.05 billion yuan, up 16.01% year on year, maintaining its position as the top imported calcium supplement brand in China for ten consecutive years. Ganxianle achieved revenue of 368 million yuan, taking the top spot in the liver disease category of Chinese patent medicines at China's public medical institutions with an 11.47% market share. In the radiosurgery business, the core product ZAP-X Mars Boat radiosurgery robot has been approved for market launch in 26 countries and regions worldwide, with more than 8,100 clinical applications, and the company plans to produce 18 units in 2026. In the innovation pipeline, Giluntai, the world's first radionuclide drug conjugate targeting integrin αvβ3, has been approved for market launch, and RAB001, an innovative drug for treating osteonecrosis, has completed Phase II enrollment in China.
Qingdao Baheal Medical INC.Baiyang Pharmaceutical's first-half net profit rose 37.72% year on year, with strong brand revenue and gross margin.
